No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...

In the world of healthcare, cancer remains one of the most daunting adversaries, known for its complex nature, high ...

XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Positive Results from Six-Month Phase 2 Trial of Mavorixafor in ...

The most challenging part of my recent pain journey was the uncertainty. But, as uncomfortable as it is, uncertainty also ...

These have included nausea, gastroparesis, bloating, fatigue, burping, stomach pain and weight gain ... Weight gain is always ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...

Understanding the symptoms of cirrhosis can facilitate early diagnosis and intervention, improving outcomes for those ...

Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...

Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...

Two pancreatic cancer survivors are sharing their stories to raise awareness about the early warning signs of the disease.

It made her feel “momentarily better”, but she sought NHS help on returning to the UK for symptoms including “nausea, severe ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.